07:00 , May 12, 2014 |  BC Week In Review  |  Company News

TNI BioTech cancer, inflammation, infectious news

TNI will spin out its wholly owned subsidiary Cytocom Inc. to operate TNI's drug development business. The newco will initially focus on developing TNI's immunotherapy products IRT-103, which is low-dose naltrexone; and IRT-101, a ...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

TNI BioTech, The Pennsylvania State University deal

TNI BioTech received exclusive rights to patents developed by three Penn State researchers from the university's Penn State Research Foundation licensing arm related to opioid receptor-targeting drugs, such as naltrexone, naloxone and met-enkephalin (opioid...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

TNI BioTech, LDN Research deal

TNI BioTech received exclusive rights to patents developed by Dr. Jill Smith and LDN relating to treatments for opioid antagonists, such as naltrexone, to treat inflammatory and ulcerative diseases of the bowel. The IP includes...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Hubei Qianjiang, TNI BioTech deal

TNI and Hubei partnered to co-develop TNI's cancer therapeutic candidates IRT-101 and IRT-102 in China. Hubei will fund all clinical development and has committed an additional RMB10 million ($1.6 million) to fund preclinical...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

TNI BioTech deal

TNI BioTech received exclusive rights to U.S. patents developed by Dr. Bernard Bihari relating to treatments with opioid antagonists such as naltrexone and met-enkephalin to treat cancer, infectious diseases and inflammatory conditions. TNI BioTech plans...